Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
This study is recruiting at 18 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Reviva Pharmaceuticals
- Last updated on ClinicalTrials.gov
- December 19, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Reviva site · Phoenix, AZ
Arkansas · 3
- Reviva site · Bentonville, AR
- Reviva site · Little Rock, AR
- Reviva site · Rogers, AR
California · 3
- Reviva site · Garden Grove, CA
- Reviva site · Lemon Grove, CA
- Reviva site · Riverside, CA
Florida · 3
- Reviva site · Hollywood, FL
- Reviva site · Hollywood, FL
- Reviva site · Miami Lakes, FL
Georgia · 2
- Reviva site · Atlanta, GA
- Reviva site · Decatur, GA
Illinois · 1
- Reviva site · Chicago, IL
Maryland · 1
- Reviva site · Gaithersburg, MD
Massachusetts · 1
- Reviva site · Boston, MA
Oklahoma · 1
- Reviva site · Oklahoma City, OK
Texas · 2
- Reviva site · Austin, TX
- Reviva site · Richardson, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.